Publication | Closed Access

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Patient-reported OutcomesHepatologyMedicineClinical TrialsPathologyBevacizumab Versus SorafenibPharmacotherapyLiver CancerCancer TreatmentOncologyRadiation OncologyUnresectable Hepatocellular CarcinomaHepatocellular CarcinomaHealth Sciences